Biomarker Discovery
Building Personalized Medicine in Ontario
Andrew Emili
Ontario Research Chair in Biomarkers of Clinical Management
Donnelly Center, UofT
2012 Symposium of Ontario Research Chairs in Public Policy
Osgoode Professional Development, March 5th, 2012
Personalized Medicine
Stem cells, ...
Genes linked to Alzheimer’s, autism, diabetes, ...
Cancer drugs tailored to treat an individual tumor, ...
Containing the Health-Care Burden
Genomic Landscape
In only a year or two, the cost of determining a person’s
complete DNA blueprint is expected to fall below $1,000.
30,000 human genomes sequenced by years end,
number will rise to millions in a few years.
Diversity: Targeting Therapies
Biomarkers: Clinical Surrogates
Informative, reliable, minimally-invasive, low cost, ...
Informative, minimally invasive, low cost,...
Biomarkers: Measurable Outcomes
Biomarkers: Clinical Assays
How Does (my) Research Fit in?
Major challenges are to:
Discover,
Interpret,
Validate,
&
Commercialize
new biomakers in the lab, clinic and marketplace
Examples: Work in Progress
1. Gramolini, Emili, Liu, MacLennan, Isserlin, Kislinger, and Roche Diagnostics. "The use of insulin like growth
factor binding protein 7 (IGFBP7) in the assessment of heart failure". Submitted January 25, 2007 to the European
Patent Office. (App # 7001582.1) (Nov 11, 2010 US Application US-2010-0285491-A1)
2. Gramolini, Emili, Liu, MacLennan, Isserlin, Kislinger, and Roche Diagnostics. "The use of skeletal muscle LIM
protein 1 isoform-1 (SLIM1) in the assessment of heart failure". Submitted March 8, 2007 to the European Patent
Office. (App # 07004740.2) (Nov 11, 2010 US Application US-2010-0285492-A1)
3. Gramolini, Emili, Liu, MacLennan, Isserlin, Kislinger, and Roche Diagnostics. "The use of Nogo-A in the assessment
of heart failure". Submitted Feb 18, 2007 to the European Patent Office. (App # 07003409.5)
4. Gramolini, Emili, Liu, MacLennan, Isserlin, Kislinger, and Roche Diagnostics. "The use of Nogo-C in the assessment
of heart failure". Submitted March 6, 2007 to the European Patent Office. (App # 07004532.3) European patent
granted #EP1967853 "Use of Nogo-C in the assessment of heart failure". Published Jan 27, 2010.
5. Gramolini, Emili, Liu, MacLennan, Isserlin, Kislinger, and Roche Diagnostics. "The use of dihydropyraminidinase
related protein 3 (DRP3) in the assessment of heart failure". Submitted March 19, 2007 to the European Patent
Office. (App # 07005540.5)
6. Gramolini, Emili, Liu, MacLennan, Isserlin, Kislinger, and Roche Diagnostics. "The use of myosin-binding protein C
in the assessment of heart failure". Submitted March 26, 2007 to the European Patent Office. (App # 07006135.3)
7. Gramolini, Emili, Liu, MacLennan, Isserlin, Kislinger, and Roche Diagnostics. "The use of calponin H2 in the
assessment of heart failure". Submitted April 2, 2007 to the European Patent Office. (App # 07006843.2)
8. Gramolini, Emili, Arab, Liu, MacLennan, Isserlin, and Roche Diagnostics. "The use of secreted frizzled-related
protein in the assessment of heart failure". Submitted May 8, 2008 to the European Patent Office. (App #
08008304.1) World patent granted #WO/2009/132815 "Use of SFRP-3 in the assessment of heart failure". Published
April 28, 2009
9. Gramolini, Emili, Arab, Liu, MacLennan, Isserlin, and Roche Diagnostics. "Use of biglycan in the assessment of
heart failure". Submitted Oct 17, 2008 to the European Patent Office. (App # 08018196.9)
10.Gramolini, Emili, Arab, Liu, MacLennan, Isserlin, and Roche Diagnostics. "Use of mimecan in the assessment of
heart failure". Submitted August 20, 2010 to the European Patent Office. (App# 26218WO)
11.Arab, Emili, Gramolini, Liu, MacLennan, and Roche Diagnostics. "Use of biglycan in the assessment of heart
failure". Submitted March 15, 2011 to the US Patent Office. (App #13/048196) (US-2011-0165592-A1; July 7, 2011)
Improving Outcomes